Illinois Municipal Retirement Fund Has $1.89 Million Stock Holdings in Medpace Holdings, Inc. $MEDP

Illinois Municipal Retirement Fund increased its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 63.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,932 shares of the company’s stock after purchasing an additional 1,524 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Medpace were worth $1,888,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its position in Medpace by 31.6% during the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after purchasing an additional 324,293 shares during the period. Wasatch Advisors LP raised its stake in shares of Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after buying an additional 116,354 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after buying an additional 24,625 shares during the last quarter. Invesco Ltd. lifted its holdings in Medpace by 18.9% in the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after buying an additional 85,517 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its stake in Medpace by 19.4% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 375,033 shares of the company’s stock valued at $210,637,000 after acquiring an additional 60,883 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have commented on MEDP. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. BMO Capital Markets cut their price target on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research note on Friday, April 24th. Royal Bank Of Canada reduced their price target on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Robert W. Baird reaffirmed a “neutral” rating and set a $547.00 price objective (up from $477.00) on shares of Medpace in a research note on Wednesday, July 8th. Finally, Barclays cut their target price on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. Two investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $469.50.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $527.93 on Tuesday. The company has a 50 day moving average price of $480.31 and a two-hundred day moving average price of $493.94. The company has a market capitalization of $15.08 billion, a PE ratio of 33.18, a PEG ratio of 2.69 and a beta of 1.15. Medpace Holdings, Inc. has a 52 week low of $306.70 and a 52 week high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. During the same period last year, the firm posted $3.67 earnings per share. The business’s quarterly revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Insider Buying and Selling

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 20.50% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.